Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651804 | 1.00 | TSHR (0.34) | TSHRMAPK1PIK3CGPRMT5WDR77 | |
| SCHEMBL17651770 | 0.91 | — | — | |
| SCHEMBL17651769 | 0.90 | — | — | |
| SCHEMBL17651814 | 0.84 | HSD17B1 (0.38) | PIK3CG | |
| SCHEMBL17651780 | 0.84 | HSD17B1 (0.38) | PIK3CG | |
| SCHEMBL19837811 | 0.78 | — | — | |
| SCHEMBL19837814 | 0.76 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL17651802 | 0.76 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL249200 | 0.73 | HSD17B1 (0.47) | PIK3CG | |
| SCHEMBL17651771 | 0.73 | TERT (0.34) | TSHRMAPK1PIK3CGALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403127-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2025-09-02 | — | — | US | disclosed |
| EP-3201201-B1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2022-01-26 | — | — | EP | disclosed |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2019-10-29 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
| EP-3201201-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | biolitec unternehmensbeteiligungs II AG (AT) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016051361-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | DHPS, DDT, PPOX | TSHR 2761/4885MAPK1 4321/4885PIK3CG 2986/4885 |
| US-12403127-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | TSHR 2761/4885MAPK1 4321/4885PIK3CG 2986/4885 |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | TSHR 2761/4885MAPK1 4321/4885PIK3CG 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.